In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

In your lipid practice, which patients with ASCVD do you prioritize for PCSK9-mediated lowering of LDL-C? Based on ODYSSEY Outcomes, what do we know about the subgroup of post-ACS patients who benefited most from alirocumab?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Stephen Nicholls, MD

Stephen Nicholls, MD

SAHMRI Deputy Director and Heart Foundation Heart Health Theme Leader Professor of Cardiology University of Adelaide Consultant Cardiologist Royal Adelaide Hospital Adelaide, Australia